Company Overview of Salix Pharmaceuticals Ltd.
Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides Xifaxan tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; Apriso to maintain remission of ulcerative colitis (UC); Moviprep and Osmoprep for cleansing of the colon as a preparation for colonoscopy in adults; Relistor for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; Solesta to treat fecal incontinence; and Deflux to treat vesicoureteral reflux. It also offers Fulyzaq for the symptomatic relief of non-infectious diarrhea in adult...
8510 Colonnade Center Drive
Raleigh, NC 27615
Founded in 1989
Key Executives for Salix Pharmaceuticals Ltd.
Founder and Chief Scientific Liaison
General Counsel, Executive Vice President, Secretary and Director
Associate Vice President of Investor Relations & Corporate Communications
Compensation as of Fiscal Year 2015.
Salix Pharmaceuticals Ltd. Key Developments
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals
Jul 27 15
RedHill Biopharma Ltd. has provided an update on its RHB-106 tasteless solid oral formulation bowel preparation development program under the worldwide exclusive license agreement with Salix Pharmaceuticals Ltd., recently acquired by Valeant Pharmaceuticals International Inc. Salix confirmed to RedHill that it continues the development of RHB-106. Salix further clarified to RedHill that the bowel purgative product referenced in Valeant's second quarter 2015 financial results presentation1 as a failed toxicology screen is not RedHill's RHB-106. RHB-106 is an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests such as colonoscopies, barium enemas or virtual colonoscopies, as well as surgical interventions, such as laparotomies. RHB-106 is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side effects and improved compliance. It is also intended to prevent patient exposure to the often unappealing taste of current products.
Valeant Pharmaceuticals International, Inc. Plans to Lay Off 258 Salix Workers
May 27 15
Valeant announced plans to lay off 258 Salix workers the day after it closed the acquisition. Salix executives received $78 million in golden parachute payments.
Salix Pharmaceuticals Ltd.(NasdaqGM:SLXP) dropped from Russell 1000 Index
Apr 9 15
Salix Pharmaceuticals Ltd. will be removed from Russell 1000 Index.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 11, 2015
February 22, 2015
Most Searched Private Companies
Sponsored Financial Commentaries